Nashville-based Cumberland Pharmaceuticals Inc. and Clinigen Group plc, based in the U.K., recently announced the promotional launch of Totect® (dexrazoxane hydrochloride), in the United States.
Totect is an FDA-approved, hospital-based emergency oncology intervention drug, indicated to treat the toxic effects of anthracycline chemotherapy in case of extravasation, which occurs when an injected medicine escapes from the blood vessels and circulates into surrounding tissues in the body. Extravasation can cause severe damage and serious complications. Totect can limit such damage without the need for additional surgeries and procedures and enable patients to continue their essential anti-cancer treatment.
"This is a significant next step for Cumberland as we build our position in oncology supportive care, while improving the quality of care for patients in the U.S.," said Cumberland Pharmaceuticals CEO A.J. Kazimi.